Pathogenicity Reclassification of Genetic Variants Related to Early-Onset Breast Cancer among Women of Mongoloid Origin
Source : https://journal.waocp.org/article_90156.html
Document Type : Research Articles Authors 1 Department of Molecular oncology and Immunology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Science, Tomsk, Russia. 2 Almazov National...
Conclusion: For the first time, 7.4% (10 out of 135) of mutations that affected the sites of post-translational modification in proteins were identified among early-onset breast cancer women of Mongoloid origin.
-
Albert Dekker4yrwhat is exactly mongoloid origin? Are we going back to Genghis Khan?
Knowledge of breast cancer and breast self-examination practices and its barriers among university female students in Bangladesh: Findings from a cross-sectional study
Source : https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0270417
Early diagnosis of breast cancer is the best approach towards its control that may result in alleviating related mortality and morbidity. This study aimed to evaluate knowledge about breast cancer...
Conclusion: Our findings highlight the need to develop, implement and promote socially, culturally and demographically appropriate educational interventions programs aimed at breast cancer and breast self-examination awareness and practice in Bangladesh.
Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35742993/
The development of HER2-targeted therapies has dramatically improved patient survival and patient management and increased the quality of life in the HER2+ breast cancer patient population. Due to the activation...
Conclusion: Currently, several clinical trials are examining the synergistic effects of CDK 4/6 inhibitors with optimized HER2-directed therapies for the (ER /-) HER2 population in the metastatic setting. In this review, we aim to interrogate the burden of HER2 disease in light of recent treatment progress in the field and examine the...
Meaning: These results did not support the interpretation of ERBB2-low as a distinct biologic subtype of breast cancer.
-
Albert Dekker4yrmakes perfect sense
A Rare Case of Non-immune Hemolytic Anemia in a Stage IV Breast Cancer Patient Treated With Capecitabine - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35698681/
Incremental changes in the diagnosis of breast cancer leave drastic impacts on patients. There are detrimental shifts in cost, psychological disorders in terms of depression, and morbidities. Stage IV breast...
Conclusion/Relevance: Stage IV breast cancer has a high mortality rate and was afflicting our patient who was diagnosed with metastatic breast cancer estrogen receptor/progesterone receptor (ER/PR) positive, human epidermal growth factor receptor 2 (HER-2) neo negative, and low Ki-67. Among the various management modalities and effective...
-
Breast Cancer Connect4yrHow would you manage this complication? What agent would you use?
-
Albert Dekker4yrHappens. Especially very advanced patients